Understanding Kidney Cancer Growth Driven by L-2HG
Official title: Interaction between the Epitranscriptome and Metabolism in L-2HG Driven Kidney Cancer
Funded at University of Alabama at Birmingham · NIH-11141123 · Data updated 2026-11-12
This work explores how a molecule called L-2HG helps kidney cancer grow, aiming to find new ways to help patients with advanced disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | August 1, 2016 |
| Project end | July 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $371,250 |
| NIH project number | 5R01CA200653-09 |
| Project ID | NIH-11141123 on NIH RePORTER |
Who could benefit from this research
✓Could help
This foundational work is not directly recruiting patients but focuses on understanding the biology of kidney cancer, particularly those with L-2HG elevations.
✕Less likely to help
Patients whose kidney cancer does not involve elevated L-2HG or those seeking immediate treatment options may not directly benefit from this basic science research.
What this research studies
We know that kidney cancer can be very challenging for patients with advanced disease, and new treatments are urgently needed. Our team has found that a specific molecule, L-2HG, is often elevated in kidney cancer cells and seems to drive their growth. This project looks closely at how L-2HG changes the genetic instructions within cancer cells and how it affects their metabolism, which is how cells get energy. By understanding these detailed processes, we hope to uncover new targets for future therapies.
Why it matters
Potential benefit: If successful, this work could lead to the development of new and more effective treatments for patients with advanced kidney cancer.
How similar studies have gone: This project explores novel connections between L-2HG, RNA modifications, and metabolism in kidney cancer, building on preliminary findings that suggest these are intricately linked.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Sudarshan, Sunil — University of Alabama at Birmingham
- Study coordinator: Sudarshan, Sunil
Related research
Other NIH-funded projects on the same topics.
-
Maximizing anti-tumor immune responses in kidney cancer
A cutting-edge program at UT Southwestern aims to speed up better immunotherapy options for kidney cancer by studying how to activate both innate and adaptive immune responses.
-
Kidney Cancer Career Enhancement Program (CEP) at DF/HCC
A career-boosting program supports junior investigators studying kidney cancer to help them advance in basic, translational, and clinical work.
-
Kidney Cancer Development Program at DF/HCC
A funded program at Dana-Farber/Brigham and Women’s Kidney Cancer Center supports new ideas from researchers to improve understanding and treatment of kidney cancer.
-
Personalized antigens for kidney cancer therapy
This grant explores identifying and targeting tumor-specific antigens in kidney cancer to develop more effective, personalized immunotherapies.
-
Optimizing Anti-PD1 Therapy for High-Risk and Metastatic Kidney Cancer
A large cancer research grant is testing how best to use anti-PD-1 therapy to help people with high-risk and metastatic kidney cancer live longer and with fewer side effects.
-
Targeting the HIF2 Pathway in Kidney Cancer
A cancer treatment program aims to see if a drug called belzutifan can help people with a specific kind of kidney cancer whose growth is driven by the HIF2 pathway.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.